Your browser doesn't support javascript.
loading
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Lin, Jessica J; Choudhury, Noura J; Yoda, Satoshi; Zhu, Viola W; Johnson, Ted W; Sakhtemani, Ramin; Dagogo-Jack, Ibiayi; Digumarthy, Subba R; Lee, Charlotte; Do, Andrew; Peterson, Jennifer; Prutisto-Chang, Kylie; Malik, Wafa; Hubbeling, Harper G; Langenbucher, Adam; Schoenfeld, Adam J; Falcon, Christina J; Temel, Jennifer S; Sequist, Lecia V; Yeap, Beow Y; Lennerz, Jochen K; Shaw, Alice T; Lawrence, Michael S; Ou, Sai-Hong Ignatius; Hata, Aaron N; Drilon, Alexander; Gainor, Justin F.
Afiliação
  • Lin JJ; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Choudhury NJ; Harvard Medical School, Boston, Massachusetts.
  • Yoda S; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Zhu VW; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Johnson TW; Harvard Medical School, Boston, Massachusetts.
  • Sakhtemani R; Department of Medicine, University of California Irvine, Orange, California.
  • Dagogo-Jack I; Pfizer Worldwide Research and Development, La Jolla, California.
  • Digumarthy SR; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Lee C; Harvard Medical School, Boston, Massachusetts.
  • Do A; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Peterson J; Harvard Medical School, Boston, Massachusetts.
  • Prutisto-Chang K; Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
  • Malik W; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Hubbeling HG; Harvard Medical School, Boston, Massachusetts.
  • Langenbucher A; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Schoenfeld AJ; Harvard Medical School, Boston, Massachusetts.
  • Falcon CJ; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Temel JS; Harvard Medical School, Boston, Massachusetts.
  • Sequist LV; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Yeap BY; Harvard Medical School, Boston, Massachusetts.
  • Lennerz JK; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Shaw AT; Harvard Medical School, Boston, Massachusetts.
  • Lawrence MS; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Ou SI; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Hata AN; Harvard Medical School, Boston, Massachusetts.
  • Drilon A; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Gainor JF; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Clin Cancer Res ; 27(10): 2899-2909, 2021 05 15.
Article em En | MEDLINE | ID: mdl-33685866
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Proteínas Tirosina Quinases / Proteínas de Fusão Oncogênica / Proteínas Proto-Oncogênicas / Resistencia a Medicamentos Antineoplásicos / Crizotinibe / Aminopiridinas / Lactamas / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged80 Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Proteínas Tirosina Quinases / Proteínas de Fusão Oncogênica / Proteínas Proto-Oncogênicas / Resistencia a Medicamentos Antineoplásicos / Crizotinibe / Aminopiridinas / Lactamas / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged80 Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article